Why the study?
Non-myocardial infarction etiologies of cardiogenic shock have risen in prevalence and treatment options including device therapies have expanded, prompting an update on current practices.
This review highlights the shifting epidemiology of cardiogenic shock toward non-ischemic etiologies and the growing role of device-mediated therapies.
Alerts clinicians to non-AMI etiologies in cardiogenic shock; leaves open optimal device selection for emerging causes.
Cardiogenic shock (CS) remains a leading cause of morbidity and mortality among patients with cardiovascular disease. In the past, acute myocardial infarction was the leading cause of CS. However, in recent years, other etiologies, such as decompensated chronic heart failure, arrhythmia, valvular disease, and post-cardiotomy, each with distinct hemodynamic profiles, have risen in prevalence. The number of treatment options, particularly with regard to device-mediated therapy has also increased. In this review, we sought to survey the medical literature and provide an update on current practices.
No takes yet. Share an insight, caveat, or question.
Olarte et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: